Shree Ganesh Remedies Ltd
Shree Ganesh Remedies Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #81 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q4 FY26 call signalled
1 of 3 strong
The short version
FY27 is expected to be a year where groundwork from FY26 translates into more visible business outcomes. FY26 was a year of consolidation, focused on groundwork rather than aggressive top-line growth.
From Shree Ganesh Remedies Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY27 is expected to be a year where groundwork from FY26 translates into more visible business outcomes.
- Block-7 expansion to begin commercial production in Q2 FY27, supporting niche and application-led molecules including CRAMS.
- CRAMS projects are transitioning from pilot trials to commercial trials, with momentum expected to gradually improve through FY27.
- CRAMS business anticipated to gain traction as the year progresses.
- No significant revenue contribution from CRAMS expected in FY26; pilot approvals ongoing, commercial scale-up anticipated in coming years.
- Base business is stable, operating in generic markets with limited growth, expected to plateau.
- New projects selected from customers include a mix of CRAMS, specialty chemicals, and pharma; not focused solely on CRAMS.
- Potential revenue from new CRAMS projects exists but timing and scale depend on customer approvals and market growth.
2 more points from Shree Ganesh Remedies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Shree Ganesh Remedies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current focus is on expansion at the Ankleshwar plant with the recently commissioned Unit 7A, expected to commission fully in the coming year.
- Dahej plant's common utilities construction has started and is currently under construction.
- Future expansion plans include the Dahej plant, which will commence after full utilization of the Ankleshwar unit.
- Timeline for Dahej plant commercialization is approximately 16 to 20 months from start, expected to start after 1 year.
- Block-7 expansion program is on track and expected to begin commercial production in Q2 FY27, supporting niche and application-led molecules including CRAMS.
- Pilot facility commissioned earlier this year is fully operational, accelerating new product development.
2 more points from Shree Ganesh Remedies Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Shree Ganesh Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has ongoing CRAMS projects with customers in Europe and Japan, with pilot trials successfully completed in Q4 FY26.
- These projects are transitioning from pilot to commercial trials, pending customer and regulatory approvals.
- The management refrains from giving project-specific revenue guidance but indicates a significant potential revenue contribution once approvals and commercialization progress.
- The company expects commercial production from Block-7 expansion from Q2 FY27, supporting niche and application-led molecules including CRAMS projects.
2 more points from Shree Ganesh Remedies Ltd's call on order book
Create a free account to keep reading this call
Shree Ganesh Remedies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹33 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Shree Ganesh Remedies Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Shree Ganesh Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Shree Ganesh Remedies Ltd Q4 FY26 results?
FY27 is expected to be a year where groundwork from FY26 translates into more visible business outcomes. FY26 was a year of consolidation, focused on groundwork rather than aggressive top-line growth.
What is Shree Ganesh Remedies Ltd share price analysis?
Shree Ganesh Remedies Ltd currently shows a below-average growth signal. The stock trades at a P/E of 40.8 with a market cap of ₹630 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shree Ganesh Remedies Ltd planning capital expenditure?
Current focus is on expansion at the Ankleshwar plant with the recently commissioned Unit 7A, expected to commission fully in the coming year.
Keep Shree Ganesh Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.